171 related articles for article (PubMed ID: 24009082)
1. Epidemiology of post-transplant malignancy in Asian renal transplant recipients: a population-based study.
Hsiao FY; Hsu WW
Int Urol Nephrol; 2014 Apr; 46(4):833-8. PubMed ID: 24009082
[TBL] [Abstract][Full Text] [Related]
2. The effect of maintenance immunosuppression medication on the change in kidney allograft function.
Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ
Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943
[TBL] [Abstract][Full Text] [Related]
3. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.
Yeh CC; Khan A; Muo CH; Yang HR; Li PC; Chang CH; Chen TL; Jeng LB; Liao CC
Exp Clin Transplant; 2020 Apr; 18(2):224-233. PubMed ID: 32133940
[TBL] [Abstract][Full Text] [Related]
4. Renal cell cancer after kidney transplantation.
Kleine-Döpke D; Oelke M; Schwarz A; Schwager Y; Lehner F; Klempnauer J; Schrem H
Langenbecks Arch Surg; 2018 Aug; 403(5):631-641. PubMed ID: 30003323
[TBL] [Abstract][Full Text] [Related]
5. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
7. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
8. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
[TBL] [Abstract][Full Text] [Related]
9. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
Su VCh; Greanya ED; Ensom MH
Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
11. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy.
Demir T; Ozel L; Gökçe AM; Ata P; Kara M; Eriş C; Özdemir E; Titiz MI
Transplant Proc; 2015 Jun; 47(5):1413-7. PubMed ID: 26093731
[TBL] [Abstract][Full Text] [Related]
12. Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients.
Tsai YF; Chen HP; Liu FC; Liu SH; Chen CY; Cheng CW; Lin JR
Oncotarget; 2016 Dec; 7(50):83784-83794. PubMed ID: 27626495
[TBL] [Abstract][Full Text] [Related]
13. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus after kidney transplantation in Japanese patients: The Japan Academic Consortium of Kidney Transplantation study.
Okumi M; Unagami K; Hirai T; Shimizu T; Ishida H; Tanabe K;
Int J Urol; 2017 Mar; 24(3):197-204. PubMed ID: 27862344
[TBL] [Abstract][Full Text] [Related]
15. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
16. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Melanoma in Renal Transplant Recipients.
Ascha M; Ascha MS; Tanenbaum J; Bordeaux JS
JAMA Dermatol; 2017 Nov; 153(11):1130-1136. PubMed ID: 28746700
[TBL] [Abstract][Full Text] [Related]
18. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?
Johnson DW; Nicol DL; Purdie DM; Preston JM; Brown AM; Hawley CM; Campbell SB; Wall D; Griffin AD; Isbel NM
Transplantation; 2002 Apr; 73(7):1158-63. PubMed ID: 11965051
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of immunosuppressive regimens in renal transplantation.
Guerra G; Ciancio G; Gaynor JJ; Zarak A; Brown R; Hanson L; Sageshima J; Roth D; Chen L; Kupin W; Tueros L; Ruiz P; Livingstone AS; Burke GW
J Am Soc Nephrol; 2011 Sep; 22(9):1758-68. PubMed ID: 21807891
[TBL] [Abstract][Full Text] [Related]
20. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
